SAPHNELO has the power to reduce lupus disease activity, helping you feel more like yourself again.*

*Compared to other lupus medicines alone. Disease activity reduction at the end of treatment was statistically significant in 3 of the 4 studies. Results may vary.

SAPHNELO is for adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are on other lupus medicines. Not for severe active lupus nephritis or central nervous system lupus.

IMPORTANT SAFETY INFORMATION

- **Do not use SAPHNELO** if you are allergic to anifrolumab-fnia or to any of the ingredients
- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you:**
  - Think you have an infection or have an infection that keeps coming back

US-104196 Expiration Date: 4/28/2027

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

WHY SAPHNELO?

IMPORTANT SAFETY INFORMATION (cont'd)

- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you: (cont'd)**
  - Are scheduled to receive a vaccination or if you think you may need a vaccination. You should not receive live vaccines during treatment with SAPHNELO
  - Have or have had cancer
  - Are receiving other biologic medicines or monoclonal antibodies
  - Are pregnant or plan to become pregnant. It is not known if SAPHNELO will harm your unborn baby. Tell your healthcare provider if you are, might be, or plan to become pregnant during treatment with SAPHNELO
    - **Pregnancy exposure registry** monitors pregnancy outcomes in women exposed to SAPHNELO. You can find out more information about the registry by calling AstraZeneca at 1-877-693-9268
  - Are breastfeeding or plan to breastfeed. It is not known if SAPHNELO passes into your breast milk

REDUCED DISEASE ACTIVITY IMPROVES LUPUS SYMPTOMS

In clinical studies, SAPHNELO reduced lupus disease activity across affected organs, improving lupus symptoms—for some people, within weeks.*†

SAPHNELO May Also Provide Additional Benefits for Some Patients

SIGNIFICANT STEROID REDUCTION

SAPHNELO is the only FDA-approved biologic for adults with moderate to severe lupus that's proven to significantly lower steroid use.*‡§

FEWER FLARES

Some patients taking SAPHNELO had fewer flares compared to those who did not have SAPHNELO added to their other lupus medications.‖

SAPHNELO is available as a once-weekly self-injection or as an infusion every 4 weeks. Talk to your doctor about the option that fits best with your lifestyle.

Individual experiences may vary. Always discuss your treatment plan with your healthcare provider.

*Compared to other lupus medicines alone.

†Disease activity reduction at the end of treatment was statistically significant in 3 of the 4 studies.

‡A reduction in steroid use was seen in 4 studies, 1 of which was statistically significant.

§In some patients on oral steroids ≥10 mg/day at the study start, the oral steroid dose was reduced to ≤7.5 mg/day.

‖Based on the limitations of this study, results are descriptive and for information only. Your experience may differ.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

US-104196 Expiration Date: 4/28/2027



IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

CAN SAPHNELO HELP YOU FEEL MORE LIKE YOURSELF AGAIN?

Talk to your doctor about adding SAPHNELO to your lupus treatment plan using the Doctor Discussion Guide.
It's designed to help you start a conversation about your lupus treatment goals and whether adding SAPHNELO could be right for you.

Scan for your personalized guide

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

US-104196 Expiration Date: 4/28/2027

SAPHNELO IV IS ADMINISTERED BY YOUR CARE TEAM

PARTNERSHIP

Your healthcare team will advise you on treatment location. It could be at your doctor's office, a hospital or infusion center.

ROUTINE

1x MONTH

SAPHNELO IV is usually given 1 time every 4 weeks so you can plan for it as a part of your monthly schedule.

TIME

30 MINUTES

The infusion typically takes about 30 minutes to give you the full dose. Think of this as a block of "me time" to catch up on things.

ADMINISTRATION

SAPHNELO IV is administered by your healthcare team through a needle placed in a vein.

IMPORTANT SAFETY INFORMATION (cont'd)

SAPHNELO may cause serious side effects, including:

- **Serious infections:** SAPHNELO can lower the ability of your immune system to fight infections. You may be at a higher risk of developing respiratory infections and shingles (herpes zoster) during treatment with SAPHNELO. Infections could be serious, leading to hospitalization or death. Tell your healthcare provider right away if you have any of the following symptoms of an infection:
  - fever, sweating, or chills
  - muscle aches
  - cough
  - shortness of breath
  - burning when urinating
  - urinating more often
  - diarrhea or stomach pain
  - warm, red, or painful skin or sores on your body

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

IMPORTANT SAFETY INFORMATION (cont'd)

SAPHNELO may cause serious side effects, including: (cont'd)

- **Allergic (hypersensitivity) reactions,** including anaphylaxis: Serious allergic reactions can happen during or after SAPHNELO administration. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of a serious allergic reaction:
  - swelling of your face, mouth, and tongue
  - breathing problems
  - fainting or dizziness
  - feeling lightheaded (low blood pressure)

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

US-104196 Expiration Date: 4/28/2027

HOW SAPHNELO WORKS

Type 1 interferon (IFN-1) plays a key role in lupus. SAPHNELO blocks IFN-1 activity.

IFN-1

are tiny messengers in your body that send signals to several types of immune cells to activate the immune system when needed. In lupus, there are elevated levels of IFN-1, which lead to an increase in IFN-1 activity and cause immune cells to attack your body.

Up to 80%

of people with active lupus have elevated levels of IFN-1 gene expression.

SAPHNELO

blocks the activity of IFN-1 by working across different parts of your body.

SAPHNELO is the first and only FDA-approved treatment for adults with moderate to severe SLE that works by blocking IFN-1 activity.

IMPORTANT SAFETY INFORMATION (cont'd)

SAPHNELO may cause serious side effects, including: (cont'd)

- **Cancer:** SAPHNELO may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

THE SAPHNELO PEN BRINGS TREATMENT TO YOU

CONVENIENCE

Use SAPHNELO at home or while traveling.*

ROUTINE

A once-weekly injection schedule makes it easy to fit SAPHNELO into your routine.

TIME

15 seconds is all it takes to inject SAPHNELO.

FLEXIBILITY

SAPHNELO can be stored at room temperature for up to 7 days if refrigeration is not possible.*

SAPHNELO is also available as a pre-filled syringe for self-injection. Talk to your doctor if you think it could be the right option for you.

Before you inject SAPHNELO, your healthcare provider may train you or a caregiver on how to give the injection. You should also read the Instructions for Use for detailed information on how to prepare and inject SAPHNELO.

*If needed, an unopened SAPHNELO Pen carton can be stored at room temperature for up to 7 days. Otherwise, store it in a refrigerator in the original carton until ready to use. Do not use it if it has been frozen or exposed to heat.

SAPHNELO HELPED REAL PATIENTS FEEL MORE LIKE THEMSELVES AGAIN



Finally, something that works for me

BRIE

If I had an opportunity to start sooner, I would've

CHANIQUA

When I started SAPHNELO, I didn't know what to expect, but it has really helped me

LYNETT MARIE

You have hope...that tomorrow is going to be a good day

OFELIA

Individual experiences may vary. Always discuss your treatment plan with your healthcare provider.

SCAN TO WATCH SAPHNELO STORIES

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of SAPHNELO include:

- Upper respiratory infections
- Bronchitis
- Infusion reactions (when given intravenously)
- Shingles (herpes zoster)
- Cough

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

DISCOVER SAVINGS AND SUPPORT

Saving on SAPHNELO

Pay as little as

[$0*]

for SAPHNELO

If you are prescribed SAPHNELO and have commercial insurance, you may be able to get SAPHNELO for as little as [$0].*

To enroll into the SAPHNELO Patient Savings Program, please visit or call **1-866-SAPHNELO (1-866-727-4635) for assistance.** Subject to eligibility and terms of use.

*The SAPHNELO Patient Savings Program is for commercially insured patients to cover patient out-of-pocket costs for SAPHNELO® (anifrolumab-fnia) and its infusion administration up to [$16,500] per calendar year. Patients with commercial insurance where the health plan does NOT cover SAPHNELO may qualify for the Denied Patient Savings Program. Subject to eligibility and terms of use. Patients must have commercial health insurance and a valid prescription for SAPHNELO. Patients who are enrolled in a state- or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico. Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance. Other restrictions may apply. Patient must be enrolled in the program before use. See full Eligibility and Terms of Use at www.saphnelo.com or call Access 360 at 1-866-727-4635, Monday–Friday, 8 AM to 6 PM ET, excluding holidays.

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

SAPHNELO Supports is here to help.
Eligible patients who join SAPHNELO Supports will receive a Welcome Kit that includes information about starting SAPHNELO, what to expect, helpful resources, and savings options.

Scan to enroll

Personalized Support Is Only a Call Away

The AstraZeneca Access 360™ program provides you with personal support and gives you access to a Patient Access Navigator who can help answer your questions about insurance coverage and out-of-pocket costs.

AstraZeneca Access 360™

Call 1-844-ASK-A360 (1-844-275-2360)

Monday through Friday, 8 AM to 6 PM ET.

The Nurse Helpline can help answer some of your questions about SAPHNELO or other available resources. Always contact your healthcare team for questions regarding your treatment.†

Call 1-866-SAPHNELO (1-866-727-4635)

Monday through Friday, 8 AM to 6 PM ET, excluding holidays.

†Decisions regarding your health and treatment of your condition should be made with your own healthcare provider. AstraZeneca Nurses cannot provide medical advice and can provide information about AstraZeneca medications only.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

What is SAPHNELO?

SAPHNELO is a prescription medicine used to treat adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.

It is not known if SAPHNELO is effective in patients with severe active lupus nephritis or severe active central nervous system lupus. It is not known if SAPHNELO is safe and effective in patients under 18 years of age.

IMPORTANT SAFETY INFORMATION

- **Do not use SAPHNELO** if you are allergic to anifrolumab-fnia or to any of the ingredients
- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you:**
  - Think you have an infection or have an infection that keeps coming back
  - Are scheduled to receive a vaccination or if you think you may need a vaccination. You should not receive live vaccines during treatment with SAPHNELO
  - Have or have had cancer
  - Are receiving other biologic medicines or monoclonal antibodies
  - Are pregnant or plan to become pregnant. It is not known if SAPHNELO will harm your unborn baby. Tell your healthcare provider if you are, might be, or plan to become pregnant during treatment with SAPHNELO
    - **Pregnancy exposure registry** monitors pregnancy outcomes in women exposed to SAPHNELO. You can find out more information about the registry by calling AstraZeneca at 1-877-693-9268
  - Are breastfeeding or plan to breastfeed. It is not known if SAPHNELO passes into your breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works.

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

SAPHNELO may cause serious side effects, including:

- **Serious infections:** SAPHNELO can lower the ability of your immune system to fight infections. You may be at a higher risk of developing respiratory infections and shingles (herpes zoster) during treatment with SAPHNELO. Infections could be serious, leading to hospitalization or death. Tell your healthcare provider right away if you have any of the following symptoms of an infection:
  - fever, sweating, or chills
  - muscle aches
  - cough
  - shortness of breath
  - burning when urinating
  - urinating more often
  - diarrhea or stomach pain
  - warm, red, or painful skin or sores on your body
- **Allergic (hypersensitivity) reactions,** including anaphylaxis: Serious allergic reactions can happen during or after SAPHNELO administration. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of a serious allergic reaction:
  - swelling of your face, mouth, and tongue
  - breathing problems
  - fainting or dizziness
  - feeling lightheaded (low blood pressure)
- **Cancer:** SAPHNELO may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers

The most common side effects of SAPHNELO include:

- Upper respiratory infections
- Bronchitis
- Infusion reactions (when given intravenously)
- Shingles (herpes zoster)
- Cough

These are not all the possible side effects of SAPHNELO. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

More Like Me Again

with SAPHNELO

For more information, visit SAPHNELO.com.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of SAPHNELO include:

- Upper respiratory infections
- Bronchitis
- Infusion reactions (when given intravenously)
- Shingles (herpes zoster)
- Cough

These are not all the possible side effects of SAPHNELO. Call your healthcare provider for medical advice about side effects.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial
Subcutaneous Use 120 mg/0.8 mL

AstraZeneca

SAPHNELO is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.
©2026 AstraZeneca. All rights reserved. US-104196 Last Updated 4/26

US-104196 Expiration Date: 4/28/2027